GLP-1 Coverage Dropped 2026: The Health Equity Crisis Nobody Is Talking About

# GLP-1 Coverage Dropped 2026: The Health Equity Crisis Nobody Is Talking About

> **Quick answer:** In 2026, roughly 12 million Americans lost insurance coverage for Wegovy and another 12 million lost Zepbound — the two most prescribed GLP-1 weight-loss drugs. At the same time, the FDA cracked down on compounded semaglutide, the $99–$300/month alternative that low-income patients used as a workaround. The result: a clear two-tiered system where wealthy Americans self-pay $1,000–$1,500/month while lower-income, Black, and Hispanic patients are disproportionately locked out of the drugs most likely to reverse America's obesity epidemic.

*This article is for informational purposes only and does not replace professional medical advice. Consult a qualified healthcare provider for decisions about your medications. This article does not constitute financial advice.*

GLP-1 coverage dropped in 2026, and the conversation has mostly focused on what patients can do about it — savings cards, appeals, manufacturer programs. That is a legitimate question. But it misses the larger story: the coverage collapse and the simultaneous FDA crackdown on compounded alternatives have quietly created a health equity crisis that mirrors the drug pricing debates that came before it. The people most likely to need obesity drugs are the least likely to afford them without coverage.

## What Happened: 12 Million People, Two Drugs, One Driving Force

The scale of the 2026 coverage retreat is striking. GoodRx research tracking commercial insurance found that approximately 12 million people lost coverage for Zepbound (tirzepatide, made by Eli Lilly) and another 12 million lost coverage for Wegovy (semaglutide, made by Novo Nordisk) as employers and insurers dropped weight-loss benefits heading into 2026. That is on top of the roughly 41 million people who already had no Wegovy coverage entering the year — a 42% year-over-year increase in the uncovered population.